Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Trump’s “big beautiful” bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era ...

The sweeping One Big Beautiful Bill Act, signed into federal law July 4, amended CMS’ drug price negotiations authority that could absolve nearly $5 billion in projected savings, according to the ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

Medicare Part D enrollees, who often pay a percentage of a drug’s cost, are expected to save a collective $1.5 billion in out-of-pocket expenses in 2026 because of the price negotiations, government ...

He will be responsible for overseeing the drug-price negotiations with the agency's pharmaceutical manufacturers. The goal of these negotiations, created by the 2022 Inflation Reduction Act, is to ...

Two asthma medications are among the 15 drugs recently selected for Medicare price-setting. That's no small matter -- one in six Americans with asthma struggles to afford their prescriptions.

The 15 drugs in the second cycle are under negotiations. The first negotiation cycle to include Medicare Part B drugs will be 2028, and CMS can select up to 20 drugs for the 2029 cycle.